LifeMD, Inc. provides virtual primary care through a direct-to-patient telehealth platform that combines telemedicine, laboratory access, pharmacy services, a 50-state affiliated medical group, an affiliated pharmacy and a U.S.-based patient care center. Company news commonly covers its Telehealth operating segment, recurring subscription revenue, patient sign-ups, gross margin trends and guidance.
Recurring updates also address LifeMD’s specialized care areas, including primary care, men’s and women’s health, weight management and hormone therapy. News items feature GLP-1 weight management offerings such as Wegovy and Foundayo, branded therapy access through manufacturer programs, preferred stock dividends, executive leadership changes and investor conference participation.
Medifast (NYSE: MED), the company behind the OPTAVIA® health and wellness program, has scheduled its Q2 2025 financial results announcement for August 4, 2025, after market close.
The company will host a conference call at 4:30 p.m. ET featuring Chairman and CEO Dan Chard and CFO Jim Maloney. The call will be available via webcast on Medifast's Investor Relations website and will remain archived through November 3, 2025. Telephone participants can dial (201) 389-0879, with playback access available through August 11, 2025.
LifeMD (Nasdaq: LFMD), a virtual primary care services provider, has announced a quarterly dividend payment for holders of its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP). The company will distribute a cash dividend of $0.5546875 per share. The dividend is payable on July 15, 2025, to shareholders of record as of July 3, 2025.
LifeMD (NASDAQ: LFMD) has partnered with Novo Nordisk to launch a limited-time $299 introductory bundle for self-pay patients prescribed Wegovy®. The bundle includes Wegovy® at $199 and LifeMD's virtual weight management program, available until June 30, 2025. After the first month, the program will cost $599 monthly with no long-term commitment required.
The collaboration strengthens LifeMD's ability to deliver FDA-approved GLP-1 medications through an integrated care experience, targeting patients seeking alternatives to compounded therapies. LifeMD's platform provides comprehensive services from virtual consultation to prescription fulfillment and ongoing support. Wegovy® is available through NovoCare® Pharmacy integration for eligible uninsured patients or those whose insurance doesn't cover weight-loss medications.
LifeMD (NASDAQ: LFMD), a virtual primary care services provider, has announced its participation in three major investor conferences in May 2025:
- H.C. Wainwright BioConnect Conference on May 20 at Nasdaq, New York City
- B. Riley Securities Conference on May 21-22 at the Ritz-Carlton, Marina Del Rey, featuring a corporate overview presentation
- Craig-Hallum Conference on May 28 at The Depot Renaissance Minneapolis Hotel
Management will conduct one-on-one meetings with investors at all events, with additional small group meetings at the Craig-Hallum conference.
LifeMD has announced plans to expand access to Wegovy® (semaglutide) through NovoCare® Pharmacy for cash-pay patients. The company will offer the FDA-approved weight loss medication at a reduced self-pay cost of $499 per month, including home delivery.
Through their virtual care platform, LifeMD provides a comprehensive weight management program featuring:
- Virtual consultations
- Lab testing
- Diet and lifestyle support
- Prescriptions for anti-obesity medications including GLP-1s
The integration with NovoCare® Pharmacy allows direct access to all FDA-approved dose strengths of Wegovy®, which is notably the first GLP-1 therapy approved in the United States for both chronic weight management and cardiovascular risk reduction in adults with obesity. The service targets uninsured patients or those whose insurance doesn't cover prescription weight-loss medications.
LifeMD (Nasdaq: LFMD), a virtual primary care services provider, has scheduled its Q1 2025 financial results announcement for May 6, 2025, after U.S. market close.
The company will host a conference call and webcast at 4:30 p.m. Eastern time to discuss the results for the three months ended March 31, 2025. Interested parties can join through multiple channels:
- Toll-Free: 800-225-9448
- International: 203-518-9708
- Conference ID: LIFEMD
A live webcast will be available, and an archived version will be accessible for replay after the event.
Medifast reported challenging Q1 2025 results with revenue declining 33.8% to $115.7 million. The health and wellness company's OPTAVIA program saw active earning coaches decrease 32.8% to 25,400, compared to 37,800 in Q1 2024.
Key financial highlights:
- Net loss of $0.8 million ($0.07 per share)
- Revenue per active coach at $4,556
- Gross profit down 33.8% to $84.2 million
- Strong balance sheet with $164.6 million in cash and no debt
CEO Dan Chard emphasized that 83% of people seeking weight loss lack confidence in maintaining long-term health improvements. The company is focusing on revitalizing its coach and customer base through enhanced tools and new products. For Q2 2025, Medifast expects revenue between $85-105 million with projected loss per share of $0.00 to $0.55.
LifeMD has acquired key assets from Optimal Human Health MD, marking its strategic entry into the women's health market. The company plans to launch a comprehensive virtual health program this summer, focusing on hormone health, bone density, metabolism, and wellness.
The acquisition brings on board Dr. Doug Lucas, Optimal's founder and women's health expert, along with a team of nurse practitioners, dietitians, and care staff. The new service will leverage LifeMD's:
- National provider network
- Lab partnerships with Quest and Labcorp
- In-house mail-order pharmacy
- Behavioral health services
- Nutrition and wellness capabilities
The move addresses significant gaps in women's healthcare, particularly in areas like perimenopause, menopause, and osteoporosis. According to market data, these sectors represent a major growth opportunity, with women making up 80% of osteoporosis cases, yet two-thirds remain undiagnosed. Services will be available through both private and government insurance.